**Introduction**

Cyclosporine (cyclosporine A, CsA) is a monopolar, cyclic polypeptide consisting of 11 amino acids (Fig.1). CsA mainly exhibits immunosuppressive activity. Moreover, it was experimentally as well as clinically demonstrated that CsA acts not only as an immunosuppressive agent but also as a drug which has beneficial effects on cells subjected to a variety of injurious conditions and was used as a useful agent for reducing cell damage (6, 14, 19). CsA, e.g., has been found to protect against dopaminergic depletion and to reduce cell death in animals models of stroke, cardiac arrest-induced and traumatic brain injury (12, 14). A membrane fluidizing effect of CsA enables to speculate on possibly increased penetration of some compounds through the cell membranes and organ barriers due to CsA (7). Indeed, CsA has been found to increase vincristine and vinblastine transport across the endothelial cell monolayer (3).

L-carnitine, a natural component of the mammalian tissue, is also capable to increase penetration of some chemical groups or drugs through biological barriers. We previously demonstrated an augmenting effect of repeated administration of L-carnitine on the anticholinesterase activity of 7-methoxytacrine (MEOTA) namely in the frontal cortex and septum (9). We therefore attempted to establish the ability of CsA to influence the anticholinesterase activity of 7-methoxytacrine (7-MEOTA).

**Material and Method**

Male Wistar albino rats, weighing 200–230 g, were purchased from Biotest Ltd., Konárovice, Czech Republic. Animals were maintained in a air-conditioned room (22±1 °C and 50±10 % of relative humidity) with 12/12 day/night standard conditions and free access to standard chow and water. The directions of the Council of the European Communities (86/609/EEC) on animal care have been duly maintained. Handling of experimental animals was performed under the supervision of the local Ethical Committee.
Animals were divided into 4 groups with 6 in each. The study design was as follows:

1. Control group was administered only saline in a single dose in an amount of 0.1 ml/100 g. p.o. and removal of the brain after 30 min.
2. Control group was administered of MEOTA in a single dose of 100 mg/kg i.m., removal of the brain after 30 min.
3. Administration of CsA in a single dose of 45 mg/kg p.o., removal of the brain after 30 min.
4. Repeated administration of CsA in three consecutive doses of 45 mg/kg p.o. separated by 24 hour intervals, removal of the brain 30 min after the last administration of the drug tested.
5. Repeated administration of CsA in three consecutive doses of 45 mg/kg p.o. separated by 24 hour intervals, application of MEOTA in a dose of 100 mg/kg i.m. after last CsA administration, removal of the brain after 30 min.

CsA was dissolved in olive oil, MEOTA was dissolved in saline, all doses tested were applied in an amount of 0.1 ml/100 g.

Animals were killed by decapitation and the following parts were prepared according to a previously described procedure: the frontal cortex, hippocampus, medial septum, and basal ganglia, respectively.

Acetylcholinesterase (AChE) activity in the homogenates (1:10) of the selected brain parts was determined using the method of Ellman et al. (4) as described elsewhere (1). Acetylthiocholine was used as the substrate and the results obtained were expressed as the number of nanomoles of the substrate hydrolyzed/min/100 mg wet weight tissue at 22 °C.

Acetylthiocholine was obtained from Lachema, Brno (Czech Republic). CsA was purchased from Sigma-Aldrich, St. Louis (USA).

Statistical significance was determined with the use of Student’s test for independent samples and differences were considered significant when p < 0.05. Statistical analyses were performed on a PC using the programme Statistica 98 edition.

**Results**

CsA generally exerts inhibitory effect on the AChE activity in the brain parts chosen in comparison with the control (i.e., the „saline“) group 1. Moreover, no differences between the single and repeated administration were observed in the frontal cortex and septum, while the enzyme activity in the hippocampus was diminished only in the case of repeated (group 4) and combined CsA + MEOTA (group 5) administration. On the contrary, the single administration of CsA was more efficacious in comparison with repeated and combined ones in the basal ganglia, irrespective of statistical significance of groups 3–5 with control group 1 (Fig. 2).

A further augmentation of inhibitory activity of MEOTA following repeated administration of CsA was observed in the frontal cortex (see statistical significance between control „MEOTA“ group 2 and CsA + MEOTA group 5 in Fig. 3). Lesser extent of this augmentation (compare „MEOTA“ group 2 vs. group 4 and „MEOTA“ group vs. group 5) was observed in the basal ganglia. No augmentation was observed in the hippocampus and septum.

**Discussion**

Besides well-known side effects of CsA as, e.g., nephrotoxicity and hepatotoxicity, numerous side effects of central origin are observed (11, 14, 20). They include almost all categories, i.e., motoric, sensitive, affective, and cognitive functions. Some of them, such as confusion, seizure, spasticity, paresis or ataxia, could be attributed to acetylcholine system dysbalance. CsA exerts a protective effect on the density of muscarinic acetylcholine receptors following experimental brain ischemia (13) and also enhances a spontaneous acetylcholine release after a brief tetanus (16). Gaudry-Talarmain and Moulian (8) demonstrated an invol...
vement of CsA in the presynaptic mechanism of acetylcholine release in Torpedo synaptosomes. A prolongation of succinylcholine-induced neuromuscular blockade following CsA was also demonstrated (10). Famiglio et al. (5) observed epileptiform electroencephalographic (EEG) activity following CsA administered intraperitoneally in rats. Behavioural changes observed during abnormal EEG pattern were obviously subtle, animals were often still or slightly rocking. However, possible involvement of cholinergic mechanism in these findings is only a subject of speculation.

Borlongan et al. (2) proved the most relevant evidence concerning the interaction of CsA and the central cholinergic transmission in the brain. They described an enhancement of the septal choline acetyltransferase immunoactivity in Wistar rats. The involvement of the septal region in the central effect of CsA is in good agreement with our observation.

We demonstrated at least the same (in case of the frontal cortex and septum), or even higher (in case of the basal ganglia) inhibition efficacy of CsA in comparison with MEOTA. Moreover, the dose of MEOTA used in our experiments is relatively high, it corresponds to LD25 (1). The enhancement of the anticholinesterase activity of MEOTA following repeated administration of L-carnitine has been previously demonstrated. L-carnitine augmented this activity in the frontal cortex and septum, and - in case of higher doses used - also in the basal ganglia (9). On the contrary, the extent of the augmentation of anticholinesterase activity of MEOTA following CsA was less pronounced. It was apparent only in the frontal cortex, and - under some circumstances - in the basal ganglia. This finding confirms previously published results supporting the higher sensitivity of AChE in the frontal cortex to the effect of tacrine and its derivatives (9). However, the above mentioned differences between L-carnitine and CsA in relation to the anticholinesterase activity of MEOTA suggest different mechanisms of this interaction.

According to the most accepted opinion CsA acts through binding with the immunophilin cyclophilin, the complex CsA/cyclophilin inhibits calcineurin (16, 17). Calcineurin has been shown to be localized throughout the brain including septum and hippocampus and it is important for nitric oxide (NO) metabolism and nuclear import of transcription factors (2, 16). There is also evidence about the involvement of calcineurin in the synthesis of AChE (18). The possible link CsA - calcineurin - synthesis of AChE claims to explain the above described changes in the AChE activity after CsA.

Acknowledgement

Authors wish to thank Mrs. J. Baigarová and Mrs. M. Zechovská for skilfull technical assistance. This work was supported by grant NL/6091–3 from the Grant Agency of the Ministry of Public Health of the Czech Republic.

References

1. Baigar J, Fusek J, Skopeč. F. Changes of cholinesterases in the blood and some tissues following administration of tacrine and its two derivatives to rats. Neurochem Int 1994;24:553–8.
2. Borlongan CV, Stahl CE, Keep MF, Elmer E, Watanabe S. Calcineurin-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats. Neurosci Lett 2000;279:73–6.
3. Demeule M, Laplante A, Sepeth-Arsé A et al. Inhibition of Pglycoprotein by cyclosporin A analogues and metabolites. Biochem Cell Biol 1999:77:47–58.
4. Ellman GL, Courtney DK, Andres V, Featherstone RMX. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmac 1961;7:88–95.
5. Famiglio L, Racusen L, Fivush B, Soliz K, Fisher R. Central nervous system toxicity of cyclosporine in a rat model. Transplantation 1989;48:316–21.
6. Farghalí H, Malek K. Immunopharmacological agents in the amelioration of hepatic injuries. Int J Immunopharmacol 1998;20:125–39.
7. Fricker G, Fahr A. Mechanism of hepatic transport of Cyclosporin A: An explanation for its cholestatic action? Yale J Biol Med 1997;70:379–90.
8. Gaudry-Talarmain YM, Moulin N. Cyclosporin A affects functions concerning acetylcholine release of cholinergic Torpedo synaptosomes. Eur J Pharmacol 1996;296:341–5.
9. Herink J, Baigar J, Svoboda Z, Kvetina J, Zvón P, Paříčka V. Effect of acetyl-L-carnitine on the anticholinesterase activity of 7-methotyramine in vivo. Voj Zdrav Listy 2001:70:87–9.
10. Imerman B, Caruso LJ. Prolonged neuromuscular block in a patient undergoing renal transplantation. J Clin Anesthesia 2000;13:540–4.
11. Jeruss J, Braun SV, Reese JC, Guillot A. Cyclosporine-induced white and gray matter central nervous system lesions in a pediatric renal transplant patient. Pediatr Transplantation 1998;2:45–50.
12. Kmoníčková E, Kameníková L, Hynie S, Farghalí H. Cyclosporin A modifies cytoplasmic calcium levels in isolated hepatocytes exposed to oxidative stress due to tert-buty1 hydroperoxide. Physiol Res 2000:49:471–4.
13. Kondo Y, Asasuma M, Ibata E, Kondo F, Miyazaki I, Ogawa N. Early treatment with cyclosporin A ameliorates the reduction of muscarinic acetylcholine receptors in gerbil hippocampus after transient forebrain ischemia. Neurochem Res 1999:24:9–13.
14. Krejčíva G, Herink J. Současné poznatky o cyklosporinu A. Voj Zdrav Listy 2002:71:in press.
15. Lin MJ, Lin-Shiau SY. Enhanced spontaneous transmitter release at murine motor nerve terminals with cyclosporine. Neuropharmacol 1999;38:195–8.
16. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991:66:807–15.
17. Lu YF, Tomizawa K, Moriwaki A et al. Calcineurin inhibitors, FK506 and cyclosporin, suppress the NMDA receptor-mediated potentials and LTP but do not potentiate in the rat hippocampus. Brain Res 1996;729:142–6.
18. Luo ZD, Wang Y, Weißen G, Camp S, Chien KR, Taylor P. Calcineurin enhances acetylcholinesterase mRNA stability during C2-C12 muscle cell differentiation. Mol Pharmacol 1999;56:886–94.
19. Matář V. Cyclosporin A. Praha: Grada Publishing, 1994:160.
20. Scheinman SJ, Reinitz ER, Petro G, Schwartz RA. Cyclosporine central neurotoxicity following renal transplantation. Transplantation 1990;49:215–6.

Submitted September 2002.
Accepted November 2002.